Coinfection
Abacavir/Lamivudine Could Be Driving Liver Damage in People with HIV/HCV Coinfection
- Details
- Category: HIV/HCV Coinfection
- Published on Saturday, 17 October 2015 00:00
- Written by Michael Carter
Progression of liver fibrosis among ART-treated patients with HIV/HCV coinfection is associated with the type of nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) "backbone," Canadian research published in the September 23 online edition of Clinical Infectious Diseases suggests.
ICAAC 2015: Comorbidities and Mortality Among HIV-Positive and HIV/HCV Coinfected People
- Details
- Category: HIV/HCV Coinfection
- Published on Thursday, 01 October 2015 00:00
- Written by Liz Highleyman
While illness and death due to opportunistic illnesses has declined, people living with HIV remain prone to comorbidities that contribute to hospitalization and reduced survival, according to presentations at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last weekin San Diego. Mortality is higher among HIV-positive people coinfected with hepatitis C virus (HCV), and is associated with liver fibrosis progression, offering further evidence supporting prompt hepatitis C treatment.
IAS 2015: HIV and Hepatitis B Coinfected People Can Safely Switch to Simpler TAF Single-Tablet Regimen
- Details
- Category: HIV/HBV Coinfection
- Published on Wednesday, 12 August 2015 00:00
- Written by Liz Highleyman
HIV-positive people with hepatitis B virus (HBV) coinfection maintained HIV viral suppression, maintained or achieved HBV suppression, and showed improvements in kidney and bone markers when they switched to a single-tablet regimen containing the integrase inhibitor elvitegravir and a new safer formulation of tenofovir, according to a late-breaking poster presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention last month in Vancouver.
Tenofovir-containing Regimen Works Better Over Time for HIV/HBV Coinfected People
- Details
- Category: HIV/HBV Coinfection
- Published on Wednesday, 16 September 2015 00:00
- Written by Liz Highleyman
HIV-positive people coinfected with hepatitis B virus (HBV) who were treated with 2 dually-active drugs -- one of them being tenofovir -- responded about as well as people taking only lamivudine or emtricitabine at 24 weeks, but over the longer term those on tenofovir plus either lamivudine or emtricitabine were more likely to maintain undetectable HBV viral load, according to a study published in a recent edition of AIDS.
IAS 2015: Daclatasvir + Sofosbuvir Cures Most Coinfected People in French Compassionate Use Study
- Details
- Category: HIV/HCV Coinfection
- Published on Wednesday, 05 August 2015 00:00
- Written by Liz Highleyman
Interferon-free treatment using daclatasvir (Daklinza) and sofosbuvir (Sovaldi), with or without ribavirin, was well-tolerated and produced sustained virological response rates of 95%-100% for HIV/HCV coinfected people with advanced liver disease, according to a presentation at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) last month in Vancouver. These results, from a French program that provides new drugs to patients in need of treatment prior to regulatory approval, demonstrate that outcomes in the "real world" can be as good as those seen in clinical trials of the new drugs.
IAS 2015: Fatty Liver May Contribute to Higher Risk of Death for HIV/HCV Coinfected People
- Details
- Category: HIV/HCV Coinfection
- Published on Wednesday, 19 August 2015 00:00
- Written by Liz Highleyman
About a quarter of HIV and hepatitis C virus (HCV) coinfected people in a New York City cohort died over a 10-year follow-up period -- a "strikingly low" survival rate -- according to a poster presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention last month in Vancouver. Researchers saw trends toward an association between steatosis (fatty liver) and cardiovascular disease, diabetes, and overall survival.
IAS 2015: Interferon-free Hepatitis Treatment Highly Effective for HIV/HCV Coinfected People
- Details
- Category: HIV/HCV Coinfection
- Published on Friday, 31 July 2015 00:00
- Written by Liz Highleyman
A trio of interferon-free regimens -- sofosbuvir/ledipasvir, AbbVie's 3D regimen, and grazoprevir/elbasvir -- were well-tolerated and cured more than 90% of HIV/HCV coinfected participants in 3 clinical trials, confirming that HIV-positive people can respond as well as HIV-negative people to modern hepatitis C treatment, according to a set of reports presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) last week in Vancouver.
IAS 2015: Accessing Hepatitis C Treatment [VIDEO]
- Details
- Category: HIV/HCV Coinfection
- Published on Wednesday, 19 August 2015 00:00
- Written by Gregory Fowler
While new interferon-free direct-acting antiviral therapy can cure more than 90% of people with chronic hepatitis C -- including those with HIV/HCV coinfection -- access to treatment remains a major challenge, experts said at a media briefing on HIV and hepatitis coinfection at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention last month in Vancouver.
IAS 2015: Effective New Treatment for HIV/HVC Coinfection [VIDEO]
- Details
- Category: HIV/HCV Coinfection
- Published on Tuesday, 28 July 2015 00:00
- Written by Gregory Fowler
Jürgen Rockstroh from the University of Bonn presented an overview of HIV/HCV coinfection during a press briefing at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention last week in Vancouver. Rockstroh covered topics including faster fibrosis progression and effective interferon-free therapy for coinfected people.
Web Design and Development by